EUVIMEDEUVIMED entdecken
Crossref

Development of a Radiogallium-Labeled Heterodivalent Imaging Probe Targeting Negative Charges and Integrin on the Surface of Cancer Cell Membranes

Takeshi Fuchigami iD, Kohei Shimo, Toya Hiwatashi, Yuka Andoh, Masayuki Munekane, Kenji Mishiro iD, Hiroaki Echigo, Hiroshi Wakabayashi, Yoji Kitamura, Seigo Kinuya, Kazuma Ogawa iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Takeshi Fuchigami und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Analytical Sciences, Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japa…. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Radiopharmaceuticals, Integrin alphaVbeta3, Cell Membrane. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Takeda Science Foundation, Shimadzu, Kobayashi Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesRadiopharmaceuticalsIntegrin alphaVbeta3Cell MembraneNeoplasmsAnimalsMiceHumansTissue DistributionCell Line, TumorPeptides, CyclicMice, NudeFemaleOligopeptidesMice, Inbred BALB C

Stichwörter der Autor:innen

Ga-67RGD peptidecationic amphiphilic peptidesintegrintheranosticstumor

Substanzen

Gallium RadioisotopesRadiopharmaceuticalsIntegrin alphaVbeta3Peptides, CyclicOligopeptidescyclic arginine-glycine-aspartic acid peptide

Autor:innen und Institutionen

  • Laboratory of Clinical Analytical Sciences, Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
  • Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
  • Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan.
  • Research Center for Experimental Modeling of Human Disease, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8640, Japan.

ORCID-Profile: Takeshi Fuchigami, Kenji Mishiro, Kazuma Ogawa

Förderung

  • Takeda Science Foundation
  • Shimadzu
  • Kobayashi Foundation for Cancer Research
  • NOVARTIS Foundation (Japan) for the Promotion of Science
  • Shibuya Science Culture and Sports Foundation
  • Japan Society for the Promotion of Science
  • Fusion Oriented REsearch for disruptive Science and Technology
  • Hitachi Global Foundation

Zitieren

APA

Fuchigami, T., Shimo, K., Hiwatashi, T., Andoh, Y., Munekane, M., Mishiro, K., Echigo, H., Wakabayashi, H., Kitamura, Y., Kinuya, S., & Ogawa, K. (2025). Development of a Radiogallium-Labeled Heterodivalent Imaging Probe Targeting Negative Charges and Integrin on the Surface of Cancer Cell Membranes. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01263

Vancouver

Fuchigami T, Shimo K, Hiwatashi T, Andoh Y, Munekane M, Mishiro K, et al. Development of a Radiogallium-Labeled Heterodivalent Imaging Probe Targeting Negative Charges and Integrin on the Surface of Cancer Cell Membranes. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01263

BibTeX
@article{Fuchigami2025,
  author = {Fuchigami, Takeshi and Shimo, Kohei and Hiwatashi, Toya and Andoh, Yuka and Munekane, Masayuki and Mishiro, Kenji and Echigo, Hiroaki and Wakabayashi, Hiroshi and Kitamura, Yoji and Kinuya, Seigo and Ogawa, Kazuma},
  title = {Development of a Radiogallium-Labeled Heterodivalent Imaging Probe Targeting Negative Charges and Integrin on the Surface of Cancer Cell Membranes},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01263}
}
Kostenlos starten →